Instem this morning released an in-line trading statement for the 2017 year. The group is seeing traction across a number of fronts, including a recovery in the Clinical business, with two Alphadas orders in the period. The company has also today announced a material SEND contract win with a top-5 global non-clinical CRO. We make no changes to estimates for 2018 and beyond, but look forward to seeing further detail on progress at the time of results in March.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Strong end to 2017 & great start to 2018…
- Published:
16 Jan 2018 -
Author:
Gareth Evans -
Pages:
3
Instem this morning released an in-line trading statement for the 2017 year. The group is seeing traction across a number of fronts, including a recovery in the Clinical business, with two Alphadas orders in the period. The company has also today announced a material SEND contract win with a top-5 global non-clinical CRO. We make no changes to estimates for 2018 and beyond, but look forward to seeing further detail on progress at the time of results in March.